PL4003533T3 - Sposoby leczenia raka wieloogniskowego - Google Patents

Sposoby leczenia raka wieloogniskowego

Info

Publication number
PL4003533T3
PL4003533T3 PL20757443.5T PL20757443T PL4003533T3 PL 4003533 T3 PL4003533 T3 PL 4003533T3 PL 20757443 T PL20757443 T PL 20757443T PL 4003533 T3 PL4003533 T3 PL 4003533T3
Authority
PL
Poland
Prior art keywords
methods
treating
multifocal cancer
cancer
treating multifocal
Prior art date
Application number
PL20757443.5T
Other languages
English (en)
Inventor
Paul Averback
Original Assignee
Nymox Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nymox Corporation filed Critical Nymox Corporation
Publication of PL4003533T3 publication Critical patent/PL4003533T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL20757443.5T 2019-07-31 2020-07-30 Sposoby leczenia raka wieloogniskowego PL4003533T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/528,390 US11231421B2 (en) 2019-07-31 2019-07-31 Methods of treating multifocal cancer
PCT/US2020/044209 WO2021022015A1 (en) 2019-07-31 2020-07-30 Methods of treating multifocal cancer

Publications (1)

Publication Number Publication Date
PL4003533T3 true PL4003533T3 (pl) 2024-07-22

Family

ID=72088374

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20757443.5T PL4003533T3 (pl) 2019-07-31 2020-07-30 Sposoby leczenia raka wieloogniskowego

Country Status (18)

Country Link
US (1) US11231421B2 (pl)
EP (1) EP4003533B1 (pl)
JP (1) JP7808545B2 (pl)
KR (1) KR20220042155A (pl)
CN (1) CN114599395A (pl)
AU (1) AU2020321022B2 (pl)
BR (1) BR112022001814A2 (pl)
CA (1) CA3149097A1 (pl)
DK (1) DK4003533T5 (pl)
ES (1) ES2981819T3 (pl)
FI (1) FI4003533T3 (pl)
HU (1) HUE066685T2 (pl)
IL (1) IL290213A (pl)
MX (1) MX2022001227A (pl)
PL (1) PL4003533T3 (pl)
PT (1) PT4003533T (pl)
WO (1) WO2021022015A1 (pl)
ZA (1) ZA202201446B (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023205629A2 (en) * 2022-04-20 2023-10-26 The Penn State Research Foundation Use of androgen receptor-mediated mechanisms in the treatment of acute myeloid leukemia

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457489A (en) 1981-07-13 1984-07-03 Gilmore Samuel E Subsea fluid conduit connections for remote controlled valves
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
DE60222745T2 (de) 2001-03-08 2008-07-10 Nymox Pharmaceutical Corp., St. Laurent Verwendung von neurofilamentproteinen zur behandlung von tumoren
BR0209990A (pt) 2001-05-25 2004-06-29 Nymox Corp Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
DE60217507T2 (de) 2001-07-19 2007-11-15 Nymox Corp., Saint-Laurent Peptide für die behandlung von tumoren und anderen zuständen, die das entfernen oder zerstören von zellen erfordern
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
PL1994152T3 (pl) 2006-02-28 2013-05-31 Nymox Corp Peptydy skuteczne w leczeniu nowotworów i innych stanów wymagających usunięcia lub zniszczenia komórek
EA200801942A1 (ru) 2006-03-10 2009-02-27 Наймокс Корпорейшн Способ предотвращения или уменьшения риска возникновения рака с использованием пептидов на основе белков нервных волокон
US9243035B2 (en) 2013-11-26 2016-01-26 Nymox Corporation Peptides effective in the treatment of conditions requiring the removal or destruction of cells
US20160215031A1 (en) 2015-01-27 2016-07-28 Nymox Pharnaceutical Corporation Method of treating disorders requiring destruction or removal of cells
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10532081B2 (en) * 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH

Also Published As

Publication number Publication date
ES2981819T3 (es) 2024-10-10
ZA202201446B (en) 2024-01-31
CA3149097A1 (en) 2021-02-04
AU2020321022A1 (en) 2022-03-03
EP4003533B1 (en) 2024-03-13
DK4003533T5 (da) 2024-07-15
BR112022001814A2 (pt) 2022-04-12
US20210033613A1 (en) 2021-02-04
IL290213A (en) 2022-03-01
CN114599395A (zh) 2022-06-07
AU2020321022B2 (en) 2025-08-07
WO2021022015A1 (en) 2021-02-04
DK4003533T3 (da) 2024-05-13
US11231421B2 (en) 2022-01-25
PT4003533T (pt) 2024-05-17
JP2022542973A (ja) 2022-10-07
MX2022001227A (es) 2022-04-06
FI4003533T3 (fi) 2024-06-10
EP4003533A1 (en) 2022-06-01
JP7808545B2 (ja) 2026-01-29
KR20220042155A (ko) 2022-04-04
HUE066685T2 (hu) 2024-08-28

Similar Documents

Publication Publication Date Title
IL275663A (en) Cancer treatment methods
IL287907A (en) Cancer treatment methods
IL277981A (en) Cancer treatment methods
IL283337A (en) Methods for treating whsc1-overexpressing cancers by inhibiting setd2
IL281600B2 (en) Cancer treatment methods
IL286297A (en) Minimal residual cancer treatment methods
SG11202010793UA (en) Methods of treating cancer
IL284850A (en) Methods of treating breast cancer with toctinib
IL287210A (en) Preparations for the treatment of tumors
ZA201908539B (en) Method of treatment of cancer
SG11202107017TA (en) Methods of treating cancer
EP4072561A4 (en) CANCER TREATMENT METHODS
IL289811A (en) A method for treating cancer
IL279591A (en) Cancer treatment methods using combination therapy
GB201820098D0 (en) Methods of cancer treatment
SG11202005163PA (en) Methods of treating cancer
HUE066685T2 (hu) Multifokális rák kezelési eljárásai
IL269123A (en) Methods of treating cancer
SG11202102240YA (en) Methods of treating psoriasis
GB201918815D0 (en) Treatment of cancer
GB201820975D0 (en) Methods of cancer treatment
IL269295A (en) Methods of treating breast cancer
HK40071758A (en) Methods of treating cancer
HK40079928A (en) Methods of treating cancer
EP4027989A4 (en) METHOD FOR TREATING CANCER